Madopar Depot (Benserazide Hydrochloride, Levodopa)

Levodopa is a precursor that crosses the blood‑brain barrier and is converted into dopamine, replenishing the deficient neurotransmitter in Parkinson's disease. Benserazide inhibits peripheral conversion, ensuring more levodopa reaches the brain for a sustained effect.

The specific dose of Madopar Depot is determined individually by a qualified prescriber based on the patient’s clinical condition, response, and tolerability. No fixed regimen is provided here.

Safety data for Madopar Depot in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician.

To order Madopar Depot, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Madopar Depot offers a prolonged release profile, delivering levodopa more steadily over time, which can reduce motor fluctuations compared with immediate‑release tablets that require multiple daily doses and may cause peaks and troughs in symptom control.

Madopar Depot should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the tablets out of reach of children.

Madopar Depot is taken orally, usually with a glass of water. It is designed as an extended‑release tablet, so it should be swallowed whole and not split, chewed, or crushed to maintain the intended release characteristics.

Serious risks include dyskinesia (involuntary movements), psychiatric disturbances such as hallucinations or confusion, and severe hypotension. Patients should be monitored closely for these events, and any concerning symptoms should be reported to a healthcare professional promptly.

Madopar Depot is contraindicated in patients with known hypersensitivity to levodopa, benserazide, or any excipients, and in individuals taking non‑selective MAO inhibitors. Caution is also advised for patients with severe cardiovascular disease, uncontrolled hypertension, or a history of malignant neuroleptic syndrome.